http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#Head
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#assertion
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#provenance
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#pubinfo
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#assertion
http://purl.obolibrary.org/obo/DOID_9253
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9253
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00619
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
http://www.w3.org/2000/01/rdf-schema#label
gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase 1 1 patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in blast crisis bc accelerated phase ap or in chronic phase cp after failure of interferon alpha therapy 1 2 adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 3 pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia ph all in combination with chemotherapy 1 4 adult patients with myelodysplastic myeloproliferative diseases mds mpd associated with pdgfr platelet derived growth factor receptor gene re arrangements as determined with an fda approved test 1 5 adult patients with aggressive systemic mastocytosis asm without the d816v c kit mutation as determined with an fda approved test or with c kit mutational status unknown 1 6 adult patients with hypereosinophilic syndrome hes and or chronic eosinophilic leukemia cel who have the fip1l1 pdgfri fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes and or cel who are fip1l1 pdgfri fusion kinase negative or unknown 1 7 adult patients with unresectable recurrent and or metastatic dermatofibrosarcoma protuberans dfsp 1 8 patients with kit cd117 positive unresectable and or metastatic malignant gastrointestinal stromal tumors gist 1 9 adjuvant treatment of adult patients following resection of kit cd117 positive gist 1 1 newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase patients with philadelphia chromosome positive chronic myeloid leukemia in blast crisis accelerated phase or in chronic phase after failure of interferon alpha therapy adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia ph all in combination with chemotherapy adult patients with myelodysplastic myeloproliferative diseases associated with pdgfr platelet derived growth factor receptor gene re arrangements as determined with an fda approved test see dosage and administration 2 6 adult patients with aggressive systemic mastocytosis without the d816v c kit mutation as determined with an fda approved test see dosage and administration 2 7 adult patients with hypereosinophilic syndrome and or chronic eosinophilic leukemia who have the fip1l1 pdgfri fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes and or cel who are fip1l1 pdgfri fusion kinase negative or unknown adult patients with unresectable recurrent and or metastatic dermatofibrosarcoma protuberans patients with kit cd117 positive unresectable and or metastatic malignant gastrointestinal stromal tumors adjuvant treatment of adult patients following complete gross resection of kit cd117 positive gist
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00619
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#provenance
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#pubinfo
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig
http://purl.org/nanopub/x/hasSignature
ZRbmjttYz8/8fNcz+7/9vPZbPlUEBMHVj2RfroMZeneTxeq0qDiyznP+cpfatpOaEfoJErLAbm3/76sGTQRmtN1TJPWvmRWQWoDZYEvOaghUUttkN6wO3FB4WN31PkNQo3rVt2h1JMGOOs328V13DMXZsVokEzJZgQWM8dvCWX4=
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
http://purl.org/dc/terms/created
2021-07-03T14:18:50.693+02:00
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs